IQVIA Holdings Valuation

Is IQV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IQV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IQV ($225) is trading below our estimate of fair value ($325.93)

Significantly Below Fair Value: IQV is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for IQV?

Other financial metrics that can be useful for relative valuation.

IQV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.6x
Enterprise Value/EBITDA19.4x
PEG Ratio2.3x

Price to Earnings Ratio vs Peers

How does IQV's PE Ratio compare to its peers?

The above table shows the PE ratio for IQV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average36.9x
A Agilent Technologies
34.5x9.0%US$43.4b
MTD Mettler-Toledo International
39.5x8.3%US$31.1b
WST West Pharmaceutical Services
41.4x10.8%US$23.9b
WAT Waters
32.2x7.9%US$19.7b
IQV IQVIA Holdings
30.2x12.9%US$41.3b

Price-To-Earnings vs Peers: IQV is good value based on its Price-To-Earnings Ratio (30.2x) compared to the peer average (36.9x).


Price to Earnings Ratio vs Industry

How does IQV's PE Ratio compare vs other companies in the US Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.8%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.8%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: IQV is good value based on its Price-To-Earnings Ratio (30.2x) compared to the Global Life Sciences industry average (32.4x).


Price to Earnings Ratio vs Fair Ratio

What is IQV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IQV PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio30.2x
Fair PE Ratio27.4x

Price-To-Earnings vs Fair Ratio: IQV is expensive based on its Price-To-Earnings Ratio (30.2x) compared to the estimated Fair Price-To-Earnings Ratio (27.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IQV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$225.00
US$271.44
+20.6%
5.5%US$295.00US$245.00n/a18
May ’25US$232.94
US$275.38
+18.2%
5.4%US$300.00US$250.00n/a19
Apr ’25US$248.87
US$273.70
+10.0%
5.7%US$300.00US$250.00n/a19
Mar ’25US$252.45
US$273.70
+8.4%
5.7%US$300.00US$250.00n/a19
Feb ’25US$211.30
US$246.33
+16.6%
6.7%US$286.00US$220.00n/a18
Jan ’25US$231.38
US$236.47
+2.2%
7.4%US$270.00US$200.00n/a19
Dec ’24US$216.91
US$229.52
+5.8%
8.4%US$258.90US$190.00n/a19
Nov ’24US$180.01
US$242.79
+34.9%
7.3%US$265.00US$210.00n/a19
Oct ’24US$196.75
US$252.16
+28.2%
5.7%US$281.00US$220.00n/a19
Sep ’24US$224.33
US$252.90
+12.7%
5.6%US$281.00US$220.00n/a20
Aug ’24US$219.13
US$252.34
+15.2%
8.0%US$285.00US$200.00n/a20
Jul ’24US$224.77
US$246.64
+9.7%
8.1%US$285.00US$200.00n/a20
Jun ’24US$198.97
US$245.64
+23.5%
8.2%US$285.00US$200.00n/a20
May ’24US$190.00
US$245.96
+29.5%
8.1%US$285.00US$200.00US$232.9421
Apr ’24US$198.89
US$258.58
+30.0%
4.6%US$285.00US$235.00US$248.8721
Mar ’24US$210.77
US$260.47
+23.6%
4.0%US$285.00US$235.00US$252.4519
Feb ’24US$233.49
US$256.58
+9.9%
5.1%US$285.00US$230.00US$211.3019
Jan ’24US$204.89
US$254.84
+24.4%
5.4%US$285.00US$230.00US$231.3819
Dec ’23US$220.55
US$255.06
+15.6%
5.6%US$285.00US$230.00US$216.9118
Nov ’23US$209.39
US$258.11
+23.3%
5.8%US$285.00US$230.00US$180.0118
Oct ’23US$181.14
US$269.11
+48.6%
6.6%US$300.00US$235.00US$196.7518
Sep ’23US$211.62
US$270.22
+27.7%
6.0%US$300.00US$235.00US$224.3318
Aug ’23US$238.37
US$265.16
+11.2%
5.6%US$290.00US$235.00US$219.1319
Jul ’23US$215.05
US$262.39
+22.0%
6.6%US$290.00US$235.00US$224.7718
Jun ’23US$210.11
US$265.59
+26.4%
7.9%US$310.00US$235.00US$198.9717
May ’23US$217.99
US$267.41
+22.7%
7.6%US$310.00US$235.00US$190.0017

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.